デフォルト表紙
市場調査レポート
商品コード
1488711

バイオテクノロジー市場- 世界の産業規模、シェア、動向、機会、予測、用途別、エンドユーザー別、地域別、市場競争別、2019年~2029年

Biotechnology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By End User, By Region and Competition, 2019-2029F

出版日: | 発行: TechSci Research | ページ情報: 英文 184 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

バイオテクノロジー市場- 世界の産業規模、シェア、動向、機会、予測、用途別、エンドユーザー別、地域別、市場競争別、2019年~2029年
出版日: 2024年06月03日
発行: TechSci Research
ページ情報: 英文 184 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

バイオテクノロジーの世界市場規模は2023年に1兆2,300億米ドルとなり、2029年までのCAGRは12.25%で、予測期間中に目覚ましい成長を遂げると予測されています。

バイオテクノロジーの世界市場は、主に業界の革新と成長を促進するいくつかの要因によって牽引されています。ゲノミクス、プロテオミクス、合成生物学を含むバイオテクノロジー研究の進歩により、新規治療法、診断法、農産物の開発の可能性が広がっています。政府、学術機関、非公開会社によるバイオテクノロジー研究開発への投資の増加は、新しいバイオテクノロジー製品や技術の発見と商業化を促進しています。個別化医療、バイオ医薬品、バイオ燃料に対する需要の高まりが、バイオテクノロジー市場の拡大を後押ししています。支持的な規制の枠組みや有利な償還政策は、バイオテクノロジー製品の承認プロセスを合理化することで市場の成長を促進しています。全体として、これらの要因が世界のバイオテクノロジー市場のダイナミックな成長と進化に寄与しています。

市場概要
予測期間 2025年~2029年
市場規模:2023年 1兆2,300億米ドル
市場規模:2029年 1兆4,000億米ドル
CAGR:2024年~2029年 12.25%
急成長セグメント バイオ医薬品
最大市場 北米

市場促進要因

バイオテクノロジー調査の進歩

個別化医療への需要の高まり

バイオテクノロジー研究開発への投資の増加

バイオ医薬品の採用拡大

主な市場課題

規制の複雑さと厳しい承認プロセス

知的財産権と特許保護

資本集約と資金調達の制約

主な市場動向

合成生物学の出現

精密医療への注目の高まり

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のバイオテクノロジー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 用途別(バイオ医薬品、バイオIT、バイオ産業、バイオ農業)
    • エンドユーザー別(バイオテクノロジー・製薬企業、研究機関・研究所、学術機関、その他)
    • 地域別
    • 企業別(2023年)
  • 市場マップ

第6章 北米のバイオテクノロジー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 用途別
    • エンドユーザー別
    • 国別
  • 北米:国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のバイオテクノロジー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 用途別
    • エンドユーザー別
    • 国別
  • 欧州:国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋のバイオテクノロジー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 用途別
    • エンドユーザー別
    • 国別
  • アジア太平洋:国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米のバイオテクノロジー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 用途別
    • エンドユーザー別
    • 国別
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのバイオテクノロジー市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 用途別
    • エンドユーザー別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併および買収(該当する場合)
  • 製品の発売(ある場合)
  • 最近の動向

第13章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第14章 競合情勢

  • Novo Nordisk A/S
  • Regeneron Pharmaceuticals Inc.
  • Amgen, Inc.
  • CSL Limited
  • Gilead Sciences, Inc.
  • Celgene Corporation
  • Biogen Inc.
  • Vertex Pharmaceuticals, Inc.
  • Seagen Inc.
  • Genmab A/S

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 7573

Global Biotechnology Market was valued at USD 1.23 Trillion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 12.25% through 2029. The Global Biotechnology Market is primarily driven by several factors fueling innovation and growth in the industry. Advancements in biotechnology research, including genomics, proteomics, and synthetic biology, are expanding the possibilities for developing novel therapies, diagnostics, and agricultural products. Increasing investments in biotechnology research and development by governments, academic institutions, and private sector companies are driving the discovery and commercialization of new biotech products and technologies. Growing demand for personalized medicine, biopharmaceuticals, and biofuels is propelling the expansion of the biotechnology market. Supportive regulatory frameworks and favorable reimbursement policies are facilitating market growth by streamlining the approval process for biotech products. Overall, these factors are contributing to the dynamic growth and evolution of the Global Biotechnology Market.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1.23 Trillion
Market Size 2029USD 1.40 Trillion
CAGR 2024-202912.25%
Fastest Growing SegmentBiopharmaceuticals
Largest MarketNorth America

Key Market Drivers

Advancements in Biotechnology Research

The Global Biotechnology Market is driven by continuous advancements in biotechnology research, which encompass various fields such as genomics, proteomics, and synthetic biology. These advancements are leading to the discovery and development of innovative biotech products and technologies with diverse applications in healthcare, agriculture, and industrial sectors. Researchers are exploring new frontiers in biotechnology, including gene editing techniques like CRISPR-Cas9, novel drug delivery systems, and advanced diagnostics, which are revolutionizing the way diseases are diagnosed and treated.

Increasing Demand for Personalized Medicine

The escalating demand for personalized medicine underscores a fundamental shift in healthcare towards more effective and precisely targeted therapies tailored to individual patient needs. At the forefront of this transformative paradigm lies biotechnology, a discipline that is revolutionizing the landscape of medicine by harnessing the power of genetic insights and molecular diagnostics.

Biotechnology serves as the cornerstone in the development of personalized therapies, facilitating the identification of genetic markers intricately linked to disease susceptibility and drug response. Through cutting-edge techniques in genomics and molecular diagnostics, biotechnologists empower healthcare providers with a comprehensive understanding of patients' genetic makeup, paving the way for customized treatment strategies that address the unique genetic underpinnings of their conditions. This personalized approach to medicine holds immense promise in enhancing clinical outcomes and patient satisfaction. By tailoring treatments to individual genetic profiles, healthcare providers can optimize therapeutic interventions, minimize adverse effects, and maximize treatment efficacy. Personalized medicine fosters a more patient-centric healthcare model, empowering individuals to actively participate in their own care journey and fostering a sense of empowerment and engagement in their treatment plans.

Rising Investments in Biotechnology R&D

Governments, academic institutions, and private sector companies are increasing their investments in biotechnology research and development (R&D). These investments are aimed at accelerating the pace of innovation, fostering collaboration between academia and industry, and translating scientific discoveries into commercially viable products. Funding initiatives, grants, and venture capital investments support biotech startups and emerging companies in developing breakthrough technologies and bringing them to market. For instance, in January 2021, Pfizer Inc. revealed that it had invested $120 million in four clinical-stage biotech firms during the latter part of 2020 as a component of the Pfizer Breakthrough Growth Initiative (PBGI). Under the PBGI, Pfizer plans to allocate up to $500 million to biotech companies, offering financial support and granting access to Pfizer's scientific knowledge to bolster the progress of promising clinical development initiatives that may align with Pfizer's strategic objectives in the future.

Growing Adoption of Biopharmaceuticals

Biopharmaceuticals, a class of therapeutic agents derived from biological sources, have emerged as a cornerstone of modern medicine, offering unparalleled precision, efficacy, and safety in the treatment of diverse medical conditions. Within the Global Biotechnology Market, the escalating adoption of biopharmaceuticals represents a pivotal driver of growth, fueled by their remarkable therapeutic potential across a spectrum of diseases.

At the forefront of this trend are biotech companies spearheading the development of innovative biologics, including therapeutic proteins, monoclonal antibodies, and gene therapies. These cutting-edge biopharmaceuticals exhibit exquisite specificity, targeting disease pathways with unprecedented precision while minimizing off-target effects. As a result, they hold tremendous promise for addressing unmet medical needs across a broad range of therapeutic areas, from oncology and immunology to neurology and rare genetic disorders. The rise of biosimilars, which are highly similar versions of already approved biopharmaceuticals, further amplifies the market's momentum. Biosimilars offer cost-effective alternatives to branded biologics, expanding patient access to life-saving treatments and fostering competition within the biopharmaceutical landscape.

Key Market Challenges

Regulatory Complexity and Stringent Approval Processes

Navigating the regulatory landscape poses a significant challenge for biotechnology companies seeking to bring innovative products to market. The stringent approval processes imposed by regulatory authorities require extensive clinical data and rigorous safety evaluations, leading to prolonged development timelines and substantial financial investments. The evolving regulatory framework, coupled with varying requirements across different geographic regions, adds complexity and uncertainty to the product development and commercialization process.

Intellectual Property Rights and Patent Protection

Intellectual property (IP) rights play a crucial role in safeguarding the innovations and investments of biotechnology companies. However, the landscape of IP protection is fraught with challenges, including patent infringement lawsuits, regulatory exclusivity periods, and the emergence of biosimilars. Maintaining a robust portfolio of patents and securing effective IP protection strategies is essential to safeguarding market exclusivity and preserving competitive advantage. Navigating the complex web of licensing agreements, technology transfers, and collaborative partnerships requires careful negotiation and strategic foresight to mitigate potential risks and ensure equitable distribution of value.

Capital Intensity and Funding Constraints

Biotechnology research and development (R&D) projects are inherently capital-intensive endeavors, requiring substantial investments in laboratory equipment, scientific expertise, and clinical trials. Securing adequate funding to support R&D activities, especially for early-stage startups and small biotech firms, remains a persistent challenge. The highly competitive nature of the industry, coupled with the inherent risks associated with drug discovery and development, can deter investors and limit access to capital. Market volatility, economic downturns, and regulatory uncertainties further exacerbate funding constraints, hindering innovation and stifling growth opportunities.

Key Market Trends

Emergence of Synthetic Biology

Synthetic biology stands at the forefront of revolutionizing biotechnology by integrating principles from biology, engineering, and computer science into a cohesive interdisciplinary field. This convergence of disciplines enables researchers and scientists to design and construct biological systems, organisms, and biomolecules with unprecedented precision and control, unlocking a myriad of possibilities for innovation and application across various domains. One of the key strengths of synthetic biology lies in its ability to engineer microorganisms for industrial biomanufacturing. By leveraging synthetic biology tools and techniques, biotech companies can tailor microorganisms to produce valuable chemicals, pharmaceuticals, biofuels, and other industrial products more efficiently and sustainably. These engineered microorganisms can be optimized to perform specific tasks, such as metabolizing waste materials or synthesizing complex molecules, leading to advancements in industrial processes and resource utilization.

In addition to industrial applications, synthetic biology holds great promise for creating bio-inspired technologies for healthcare and environmental remediation. Researchers are exploring novel approaches to engineering biological systems that mimic natural processes, such as photosynthesis or cell signaling, to develop new diagnostic tools, therapeutics, and environmental remediation solutions. For example, synthetic biology-based sensors could detect environmental pollutants or pathogens, while engineered microorganisms could be deployed to clean up contaminated sites or produce biofuels from renewable sources.

Increasing Focus on Precision Medicine

Precision medicine, also known as personalized medicine, is transforming healthcare by tailoring medical treatments to individual patients based on their genetic, environmental, and lifestyle factors. Biotechnology enables the discovery of biomarkers, diagnostic tests, and targeted therapies that enable precision medicine approaches for diseases such as cancer, cardiovascular disorders, and neurological conditions. Collaborative efforts between biotech companies, academic institutions, and healthcare providers are driving the adoption of precision medicine strategies globally, leading to more effective and personalized patient care.

Segmental Insights

Application Insights

Based on the Application, biopharmaceuticals emerge as a dominant force, driving innovation, growth, and transformative impact in healthcare. Biopharmaceuticals, also known as biologics, comprise a wide range of therapeutic products derived from biological sources, including proteins, antibodies, vaccines, and cell-based therapies. These advanced biologic medicines offer unique advantages over traditional small molecule drugs, such as higher specificity, reduced toxicity, and enhanced efficacy, making them indispensable in the treatment of various diseases, including cancer, autoimmune disorders, and rare genetic conditions.

The dominance of biopharmaceuticals in the global biotechnology market can be attributed to several key factors. The growing demand for personalized medicine and targeted therapies has fuelled the development and adoption of biologics, as they enable tailored treatments based on patients' genetic makeup and disease profiles. Advances in biotechnology platforms, such as recombinant DNA technology, monoclonal antibody production, and gene editing techniques, have revolutionized the discovery, development, and manufacturing of biopharmaceuticals, facilitating the rapid expansion of the biologics pipeline. The biopharmaceutical sector benefits from robust regulatory frameworks, favorable reimbursement policies, and increasing investment in research and development (R&D) by pharmaceutical companies, biotech startups, and academic institutions. The biologics market continues to attract significant investment due to its high growth potential, attractive return on investment (ROI), and promising therapeutic opportunities across a wide range of therapeutic areas.

End User Insights

Based on the end user segment, Biotechnology & Pharmaceutical Companies emerge as the dominant force, driving innovation, research, and commercialization of biotechnological advancements. These companies play a pivotal role in translating scientific discoveries into tangible products and therapies that address unmet medical needs, improve patient outcomes, and drive economic growth. Biotechnology & Pharmaceutical Companies leverage a multidisciplinary approach, combining expertise in molecular biology, genetics, biochemistry, and pharmacology to develop a diverse portfolio of biologics, small molecule drugs, and diagnostics across various therapeutic areas. One of the key factors contributing to the dominance of Biotechnology & Pharmaceutical Companies is their significant investment in research and development (R&D), which fuels innovation and drives the discovery of novel therapeutic targets, drug candidates, and diagnostic tools. These companies allocate substantial resources towards drug discovery platforms, high-throughput screening technologies, and clinical development programs, enabling them to bring new therapies to market efficiently and effectively.

Biotechnology & Pharmaceutical Companies possess extensive infrastructure, manufacturing capabilities, and global distribution networks, allowing them to scale production, meet regulatory requirements, and commercialize biotechnological products on a global scale. These companies invest in state-of-the-art facilities, including bioprocessing plants, research laboratories, and quality control centers, to ensure product quality, safety, and compliance with regulatory standards.

Regional Insights

North America emerges as the dominant region in the Global Biotechnology Market, driven by several key factors that position it at the forefront of biotechnological innovation, research, and commercialization. One of the primary reasons for North America's dominance in the biotechnology market is its robust ecosystem for scientific research, technological innovation, and entrepreneurship. The region is home to a concentration of world-renowned research institutions, academic centers, and biotechnology hubs, such as the renowned biotech clusters in Boston, San Francisco, and San Diego. These clusters foster collaboration between academia, industry, and government, facilitating knowledge exchange, technology transfer, and the formation of biotech startups and spin-off companies.

North America boasts a strong regulatory framework and supportive policy environment that encourages investment in biotechnology R&D, facilitates clinical trials, and expedites the approval process for biopharmaceuticals and medical devices. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada provide clear guidelines and pathways for the development and commercialization of biotechnological products, ensuring safety, efficacy, and quality standards are met. North America attracts substantial investment in biotechnology from venture capital firms, private equity investors, and corporate entities, fueling the growth of biotech startups and fostering a culture of innovation and entrepreneurship. The availability of capital, coupled with access to top-tier talent, infrastructure, and research resources, enables biotechnology companies in North America to pursue ambitious R&D projects, develop cutting-edge therapies, and bring novel products to market.

Key Market Players

Novo Nordisk A/S

Regeneron Pharmaceuticals Inc.

Amgen, Inc.

CSL Limited

Gilead Sciences, Inc.

Celgene Corporation

Biogen Inc.

Vertex Pharmaceuticals, Inc.

Seagen Inc.

Genmab A/S

Report Scope:

In this report, the Global Biotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biotechnology Market, By Application:

    Biopharmaceuticals Bio-IT Bio- Industrial Bio-Agriculture

Biotechnology Market, By End User:

    Biotechnology & Pharmaceutical Companies Research Institutes & Laboratories Academic Institutions Others

Biotechnology Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biotechnology Market.

Available Customizations:

Global Biotechnology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biotechnology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Biopharmaceuticals, Bio-IT, Bio- Industrial, Bio-Agriculture)
    • 5.2.2. By End User (Biotechnology & Pharmaceutical Companies, Research Institutes & Laboratories, Academic Institutions, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2023)
  • 5.3. Market Map

6. North America Biotechnology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biotechnology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Biotechnology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Biotechnology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By End User

7. Europe Biotechnology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biotechnology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Biotechnology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Biotechnology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By End User
    • 7.3.4. France Biotechnology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Biotechnology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By End User

8. Asia-Pacific Biotechnology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Biotechnology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By End User
    • 8.3.2. India Biotechnology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Biotechnology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Biotechnology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Biotechnology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By End User

9. South America Biotechnology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Biotechnology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Biotechnology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Biotechnology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By End User

10. Middle East and Africa Biotechnology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Biotechnology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Biotechnology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Biotechnology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Novo Nordisk A/S
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Regeneron Pharmaceuticals Inc.
  • 14.3. Amgen, Inc.
  • 14.4. CSL Limited
  • 14.5. Gilead Sciences, Inc.
  • 14.6. Celgene Corporation
  • 14.7. Biogen Inc.
  • 14.8. Vertex Pharmaceuticals, Inc.
  • 14.9. Seagen Inc.
  • 14.10. Genmab A/S

15. Strategic Recommendations

16. About Us & Disclaimer